Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)
Related Experiment Video
Updated: Jun 8, 2026

Influenza A Virus Studies in a Mouse Model of Infection
Published on: September 7, 2017
Patricia Fellows1, Jeffrey Adamovicz, Justin Hartings
1DynPort Vaccine Company, A CSC Company, 64 Thomas Johnson Drive, Frederick, MD 21702, United States. pfellows@csc.com
Abstract:
Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into naïve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.

